CTLA4 and melanoma: Immune checkpoint blockade (ICB) is widely used in the treatment of melanomas, especially those with negative regulators, such as T-lymphocyte associated protein-4 (CTLA-4), programmed death receptor 1 (PD-1), and the ligands of PD-1 (PD-L1).